Literature DB >> 26672094

Evidence of Extrapancreatic Glucagon Secretion in Man.

Asger Lund1, Jonatan I Bagger1, Nicolai J Wewer Albrechtsen2, Mikkel Christensen1, Magnus Grøndahl3, Bolette Hartmann4, Elisabeth R Mathiesen5, Carsten P Hansen6, Jan H Storkholm6, Gerrit van Hall7, Jens F Rehfeld8, Daniel Hornburg9, Felix Meissner9, Matthias Mann10, Steen Larsen3, Jens J Holst4, Tina Vilsbøll3, Filip K Knop11.   

Abstract

Glucagon is believed to be a pancreas-specific hormone, and hyperglucagonemia has been shown to contribute significantly to the hyperglycemic state of patients with diabetes. This hyperglucagonemia has been thought to arise from α-cell insensitivity to suppressive effects of glucose and insulin combined with reduced insulin secretion. We hypothesized that postabsorptive hyperglucagonemia represents a gut-dependent phenomenon and subjected 10 totally pancreatectomized patients and 10 healthy control subjects to a 75-g oral glucose tolerance test and a corresponding isoglycemic intravenous glucose infusion. We applied novel analytical methods of plasma glucagon (sandwich ELISA and mass spectrometry-based proteomics) and show that 29-amino acid glucagon circulates in patients without a pancreas and that glucose stimulation of the gastrointestinal tract elicits significant hyperglucagonemia in these patients. These findings emphasize the existence of extrapancreatic glucagon (perhaps originating from the gut) in man and suggest that it may play a role in diabetes secondary to total pancreatectomy.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26672094     DOI: 10.2337/db15-1541

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  42 in total

1.  Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Authors:  Emilie Bahne; Emily W L Sun; Richard L Young; Morten Hansen; David P Sonne; Jakob S Hansen; Ulrich Rohde; Alice P Liou; Margaret L Jackson; Dayan de Fontgalland; Philippa Rabbitt; Paul Hollington; Luigi Sposato; Steven Due; David A Wattchow; Jens F Rehfeld; Jens J Holst; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  JCI Insight       Date:  2018-12-06

2.  Enteroendocrine K and L cells in healthy and type 2 diabetic individuals.

Authors:  Tina Jorsal; Nicolai A Rhee; Jens Pedersen; Camilla D Wahlgren; Brynjulf Mortensen; Sara L Jepsen; Jacob Jelsing; Louise S Dalbøge; Peter Vilmann; Hazem Hassan; Jakob W Hendel; Steen S Poulsen; Jens J Holst; Tina Vilsbøll; Filip K Knop
Journal:  Diabetologia       Date:  2017-09-28       Impact factor: 10.122

Review 3.  Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Authors:  Magnus F Grøndahl; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  Curr Diab Rep       Date:  2017-10-28       Impact factor: 4.810

4.  Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.

Authors:  Nicolai J Wewer Albrechtsen; Kristine Færch; Troels M Jensen; Daniel R Witte; Jens Pedersen; Yuvaraj Mahendran; Anna E Jonsson; Katrine D Galsgaard; Marie Winther-Sørensen; Signe S Torekov; Torsten Lauritzen; Oluf Pedersen; Filip K Knop; Torben Hansen; Marit E Jørgensen; Dorte Vistisen; Jens J Holst
Journal:  Diabetologia       Date:  2018-01-05       Impact factor: 10.122

5.  Genetic determinants of circulating GIP and GLP-1 concentrations.

Authors:  Peter Almgren; Andreas Lindqvist; Ulrika Krus; Liisa Hakaste; Emilia Ottosson-Laakso; Olof Asplund; Emily Sonestedt; Rashmi B Prasad; Esa Laurila; Marju Orho-Melander; Olle Melander; Tiinamaija Tuomi; Jens Juul Holst; Peter M Nilsson; Nils Wierup; Leif Groop; Emma Ahlqvist
Journal:  JCI Insight       Date:  2017-11-02

Review 6.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

7.  Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis.

Authors:  Yuxin Wu; Quan Pan; Hui Yan; Kebin Zhang; Xiaoqin Guo; Zihui Xu; Wanbao Yang; Yajuan Qi; Cathy A Guo; Caitlyn Hornsby; Lin Zhang; Aimin Zhou; Ling Li; Yunmei Chen; Weiping Zhang; Yuxiang Sun; Hongting Zheng; Fred Wondisford; Ling He; Shaodong Guo
Journal:  Diabetes       Date:  2018-09-10       Impact factor: 9.461

8.  Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic GluCreERT2;ROSA26-eYFP mice.

Authors:  Dipak Sarnobat; R Charlotte Moffett; Victor A Gault; Neil Tanday; Frank Reimann; Fiona M Gribble; Peter R Flatt; Nigel Irwin
Journal:  Peptides       Date:  2019-11-16       Impact factor: 3.750

Review 9.  Actions of glucagon-like peptide-1 receptor ligands in the gut.

Authors:  Jens Juul Holst; Daniel Bjørklund Andersen; Kaare Villum Grunddal
Journal:  Br J Pharmacol       Date:  2021-08-04       Impact factor: 8.739

10.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.